The US FDA's Office of Prescription Drug Promotion (OPDP) found few objectionable drug promotions in 2018, issuing only seven letters in what seems to be another year of the agency reassessing its approach to Rx communications rather than making a public push on any enforcement priorities.
OPDP's tally was just two more than the record low of five sent in 2017. An additional untitled letter was issued by the Center for Biologics Evaluation and Research's Advertising and Promotional Labeling Branch